Misplaced Pages

Racivir

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Medication Pharmaceutical compound
Racivir
Clinical data
Routes of
administration		Investigational
ATC code
  • none
Identifiers
IUPAC name
  • 4-amino-5-fluoro-1--1,2-dihydropyrimidin-2-one
CAS Number
PubChem CID
ChemSpider
UNII
NIAID ChemDB
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC8H10FN3O3S
Molar mass247.24 g·mol
3D model (JSmol)
SMILES
  • c1c(c(nc(=O)n12CS(O2)CO)N)F
InChI
  • InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m1/s1
  • Key:XQSPYNMVSIKCOC-RITPCOANSA-N

Racivir is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Pharmasset for the treatment of HIV. It is the enantiomer of emtricitabine, a widely used NRTI, meaning that the two compounds are mirror images of each other.

Emtricitabine, the enantiomer of racivir and a widely used NRTI

References

  1. "Racivir". AIDSmeds.com. March 24, 2006. Archived from the original on 2014-01-02. Retrieved March 21, 2008.


Stub icon

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)
Capsid inhibitors
Entry/fusion inhibitors
(Discovery and development)
Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))
Maturation inhibitors
Protease Inhibitors (PI)
(Discovery and development)
1 generation
2 generation
Reverse-transcriptase
inhibitors (RTIs)
Nucleoside and
nucleotide (NRTI)
Non-nucleoside (NNRTI)
(Discovery and development)
1 generation
2 generation
Combined formulations
Pharmacokinetic boosters
Experimental agents
Uncoating inhibitors
Transcription inhibitors
Translation inhibitors
BNAbs
Other
Failed agents
°DHHS recommended initial regimen options. Formerly or rarely used agent.
Categories: